<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163536</url>
  </required_header>
  <id_info>
    <org_study_id>P17/15_corticop</org_study_id>
    <nct_id>NCT04163536</nct_id>
  </id_info>
  <brief_title>Comparison of Corticosteroids Versus Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the Intensive Care Unit</brief_title>
  <acronym>Corticop</acronym>
  <official_title>Comparison of Corticosteroids Versus Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the Intensive Care Unit: a Multicentre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine if the systemic (intravenous) administration
      of corticosteroids, as compared to placebo, increases the number of ventilator-free days
      (VFD) and alive at day 28 in COPD patients admitted to an ICU, a step-up unit or a
      respiratory care unit for an ACRF requiring ventilatory support, either invasive or
      non-invasive.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of ventilator-free days (VFD) and alive at day 28.</measure>
    <time_frame>day 28</time_frame>
    <description>To determine if the systemic administration of corticosteroids, as compared to placebo, increases the number of ventilator-free days (VFD) and alive at day 28 in COPD patients admitted to an ICU, a step-up unit or a respiratory care unit for an ACRF requiring ventilatory support, either invasive or non-invasive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIV failure rate</measure>
    <time_frame>day 7</time_frame>
    <description>NIV failure rate, defined by intubation within day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of NIV and of invasive mechanical ventilation</measure>
    <time_frame>at day 90</time_frame>
    <description>Duration of Non Invasive Ventilation and of invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulatory and renal support-free days and alive at day 28</measure>
    <time_frame>at day 28</time_frame>
    <description>Circulatory and renal support-free days and alive at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hyperglycemia requiring intravenous insulin during the five first days</measure>
    <time_frame>during the five first days</time_frame>
    <description>Severe hyperglycemia requiring intravenous insulin during the five first days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal bleeding</measure>
    <time_frame>between inclusion and day 28</time_frame>
    <description>acute loss of 2 g/dL of hemoglobin requiring red blood cell transfusion or gastroscopic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncontrolled arterial hypertension</measure>
    <time_frame>between inclusion and day 28</time_frame>
    <description>unusual hypertension requiring to introduce/add antihypertensive medication (compared to usual medications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU acquired weakness (MRC-score &lt; 48/60) assessed on day 28 or at the time of ICU discharge</measure>
    <time_frame>at day 28</time_frame>
    <description>Intensive Care Unit acquired weakness (MRC-score &lt; 48/60) assessed on day 28 or at the time of ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-acquired infections (especially Ventilator-Associated Pneumonia)</measure>
    <time_frame>at the time of ICU discharge or day 90</time_frame>
    <description>Intensive Care Unit -acquired infections (especially Ventilator-Associated Pneumonia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU and hospital stay</measure>
    <time_frame>at day 90</time_frame>
    <description>Length of ICU and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital mortality</measure>
    <time_frame>between inclusion and day 28 or day 90</time_frame>
    <description>ICU and hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 and Day 90 mortality</measure>
    <time_frame>at Day 28 and Day 90</time_frame>
    <description>Day 28 and Day 90 mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized mortality ratio (SMR)</measure>
    <time_frame>between inclusion and day 90</time_frame>
    <description>Standardized mortality ratio (SMR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new exacerbation(s)/hospitalization(s) between hospital discharge and Day 90</measure>
    <time_frame>at day 90</time_frame>
    <description>Number of new exacerbation(s)/hospitalization(s) between hospital discharge and Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score</measure>
    <time_frame>at day 90</time_frame>
    <description>Dyspnea (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory comfort (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score</measure>
    <time_frame>at day 90</time_frame>
    <description>respiratory comfort (patient reported outcome) at Day 90 evaluated by clinical assessment test and dyspnea mMRC score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>cortisteroids arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.</description>
    <arm_group_label>cortisteroids arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged ≥ 40 years

          2. Strongly suspected or documented COPD, defined by the presence of the following
             criterias:

               -  Persistent respiratory symptoms (dyspnoea, chronic cough or sputum)

               -  History of exposure to a risk factor such as tobacco smoke

               -  If available, pulmonary function tests showing airflow limitation not fully
                  reversible (post-bronchodilator ratio of FEV1/ FVC ratio &lt; 0.7)

          3. ACRF, defined by the presence of the two following criteria:

               -  COPD exacerbation defined by a change in the patient baseline respiratory
                  symptoms at least 24 hours and requiring a change in regular respiratory
                  medication

               -  Acute respiratory failure &lt;24h (polypnea ≥ 30 breaths.min-1 or use of accessory
                  respiratory muscles) requiring ventilatory support, either invasive (implemented
                  because of respiratory distress) or NIV (implemented because of hypercapnic
                  acidosis with PaCO2 ≥ 45 mmHg and pH ≤ 7.35).

          4. Admission to an ICU, a step-up unit or a respiratory care unit

          5. Inform consent from the patient or his surrogates. In patients who are not able to
             consent on admission an emergency inclusion procedure will be allowed, with a
             mandatory delayed consent.

          6. Affiliation to (or benefit from) French health insurance system

        Exclusion Criteria:

          -  Previous diagnostic of asthma, according to &quot;GINA&quot; international guidelines (40)

          -  Recent use of systemic corticosteroids, defined by systemic corticosteroids use in the
             past 7 days

          -  Contra-indication of systemic corticosteroids treatment: allergy to corticosteroids,
             uncontrolled severe arterial hypertension, uncontrolled diabetes mellitus,
             gastro-intestinal ulcer bleeding

          -  Pneumothorax at randomization

          -  Extracorporeal life support (ECMO or ECCO2R) at inclusion

          -  Moribund patient life expectancy &lt; 3 months

          -  Pregnancy

          -  Patients protected by law

          -  Exclusion period due to other interventional clinical trial enrolment which can
             influence primary outcome

          -  Previous inclusion in the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>virginie chatagner</last_name>
    <phone>0139239776</phone>
    <email>vchatagner@ch-versailles.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>André Mignot Hospital, Intensive care unit</name>
      <address>
        <city>Le chesnay</city>
        <state>Les Yvelinnes</state>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Alexis FERRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH métropole savoie</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Vincent Peigne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Armand Mekontso-Dessap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean Pierre Quenot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nicolas Terzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nadia Anguel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christophe Guitton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Saad NSEIR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mehdi MEZIDI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Michel Muller, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean Reignier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Toufik Kamel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jean daniel Chiche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital européen Georges pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Benjamin Planquette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Alexandre Demoule</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Arnaud Thille</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Arnaud Gacouin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gaëtan Beduneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stéphane Ehrmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Alexis FERRE</investigator_full_name>
    <investigator_title>coordinating investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

